Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?

被引：0
|
作者：
Gianfranco Ferraccioli
Barbara Tolusso
Elisa Gremese
机构：
[1] Catholic University of the Sacred Heart,Institute of Rheumatology, School of Medicine
[2] Catholic University of the Sacred Heart,Institute of Rheumatology, Fondazione Policlinico Gemelli
来源：
Arthritis Research & Therapy | / 18卷
关键词：
Rituximab; Low dose; High dose; Synovial tissue B cell depletion; Peripheral B cell depletion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in terms of the American College of Rheumatology (ACR)20 and ACR50, but not the ACR70. The choice should always be made after considering that the IMAGE trial has demonstrated similar radiographic progression after the first 6 months, but with less control, with low-dose rituximab in the first 6 months. A possible alternative can be hypothesized.
引用
收藏
相关论文
共 50 条
  • [31] Treat-to-Target Approach in Daily Clinical Practice in Pakistani Patients with Early Rheumatoid Arthritis
    Farman, Sumaira
    Ahmad, Nighat Mir
    Saeed, Muhammad Ahmed
    Asad, Kanwal
    Shabbir, Ghulam
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2015, 25 (02): : 129 - 133
  • [32] Adjustment in the clinical practice of treat-to-target guidelines for rheumatoid arthritis: Results of the ToARCan study
    Naranjo, Antonio
    Caceres, Laura
    Hernandez-Beriain, Jose Angel
    Francisco, Felix
    Ojeda, Soledad
    Talaverano, Sigrid
    Novoa-Medina, Javier
    Adan Martin, Jose
    Delgado, Esmeralda
    Trujillo, Elisa
    Alvarez, Ftima
    Magdalena, Laura
    Rodriguez-Lozano, Carlos
    REUMATOLOGIA CLINICA, 2016, 12 (01): : 34 - 38
  • [33] Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis: Results from the dose-ranging assessment international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) study.
    van Vollenhoven, RF
    Schechtman, J
    Szczepanski, LJ
    Fleischmann, RM
    Hazleman, BL
    Nash, PT
    Li, NF
    Sewell, KL
    Rowe, KA
    Tyrrell, H
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S711 - S711
  • [34] SUSTAINED CLINICAL RESPONSE IN REFRACTORY RHEUMATOID ARTHRITIS PATIENTS WITH A LOW-DOSE RITUXIMAB RETREATMENT REGIMEN
    Rodriguez Garcia, S. D. L. C.
    Castellanos-Moreira, R.
    Hernandez-Miguel, M. V.
    Cuervo, A.
    Ruiz-Esquide, V.
    Ramirez, J.
    Camacho, O.
    Canete, J. D.
    Gomez Puerta, J.
    Sanmarti, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1395 - 1395
  • [35] LOW DOSE OF RITUXIMAB IS EFFECTIVE FOR MAINTENANCE OF CLINICAL REMISSION OR LOW DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Argoustidis, N.
    Flouri, I.
    Adamichou, C.
    Kabouraki, E.
    Eskitzis, A.
    Kyfonidou, P.
    Papalopoulos, I.
    Fanouriakis, A.
    Repa, A.
    Kougkas, N.
    Bertsias, G.
    Sidiropoulos, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 577 - 577
  • [36] Ultrasound and its clinical use in rheumatoid arthritis: where do we stand?
    do Prado, Aline Defaveri
    Staub, Henrique Luiz
    Bisi, Melissa Claudia
    da Silveira, Ines Guimaraes
    Mendonca, Jose Alexandre
    Polido-Pereira, Joaquim
    Fonseca, Joao Eurico
    ADVANCES IN RHEUMATOLOGY, 2018, 58 : 19
  • [37] Ultrasound and its clinical use in rheumatoid arthritis: where do we stand?
    Aline Defaveri do Prado
    Henrique Luiz Staub
    Melissa Cláudia Bisi
    Inês Guimarães da Silveira
    José Alexandre Mendonça
    Joaquim Polido-Pereira
    João Eurico Fonseca
    Advances in Rheumatology, 58
  • [38] The new criteria for classification of rheumatoid arthritis: what we need to know for clinical practice
    Corrao, Salvatore
    Calvo, Luigi
    Licata, Giuseppe
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2011, 22 (03) : 217 - 219
  • [39] Factors associated with long-term persistence of rituximab in rheumatoid arthritis In clinical practice: RITAR Study
    Canamares Orbis, Iciar
    Merino Melendez, Leticia
    Llorente Cubas, Irene
    Benedi Gonzalez, Juana
    Garcia-Vicuna, Rosario
    Morell Baladron, Alberto
    Gonzalez-Alvaro, Isidoro
    Ramirez Herraiz, Esther
    MEDICINA CLINICA, 2020, 155 (01): : 1 - 8
  • [40] DISEASE ACTIVITY GUIDED TAPERING OF RITUXIMAB IN CLINICAL PRACTICE: A RETROSPECTIVE COHORT STUDY OF RHEUMATOID ARTHRITIS PATIENTS
    Wientjes, M.
    Van Huissteden, J.
    Verhoef, L. M.
    Den Broeder, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 313 - 314
12345